760 likes | 1.12k Views
Presentation Outline. Description of compoundClinical development programDose-finding studiesEfficacy trialsSupportive studiesProposed indication and dosingConclusions. ICL670 (Exjade?, deferasirox). Formulated as dispersible tabletHighly specific for iron70% oral bioavailability, increased
E N D